Biolog Devices (CEO Hwang Hoon), a KOSDAQ listed company, announced on the 30th that Salvacion, an affiliated company, was introduced to the Clinical Trials Arena, a media that reports clinical research trends in major countries, on the 27th US time.
As an alternative to overcome the morphological limitations of traditional treatment methods such as injections, oral treatments, and vaccines, Clinical Trial Arena introduced five types of nasal spray-use coronavirus killers as a special feature article. Based on this, Pharmaceutical-Technology and Fuentitech, which report biotechnology trends, cited this news and reported it.
Among them, Salvacion’s corona killing agent ‘COVIXYL-V’ was introduced for the first time and attracted attention. ‘COVIXYL-V’ reported that it showed a killing effect of 99.99% in both in-vivo and in-vitro studies with the support of the US National Cancer Institute (NCI), and is waiting for commercial use approval.
Next, Amimite Pharmaceutical’s ‘Nacitrol’, IGM Viosys’ ‘IGM-6268’, Marinoid Biotechnology’s ‘Caregros’, and Marge Canada Sanotiz’s nitric oxide nasal spray ‘Enovid’ were introduced.
In the case of ‘Enovid’, an emergency use license was obtained in Israel in early July after the results of the second phase experiment showed that it reduced the virus transmission in humans by reducing the SARS-CoV-2 virus load. It provides a physical and chemical barrier to the nose by releasing a small amount of nitrogen oxide, a natural nanomolecule with antimicrobial properties such as SARS-CoV-2. Products currently undergoing clinical trials at Jinwon Life Sciences in Korea also use the nitrogen oxide mechanism. The company is awaiting approval in several other countries, including Canada, India, Brazil and Mexico.
Meanwhile, Salvacion, which developed Covixyl-v, is a company invested by KOSDAQ Biolog Devices through a subsidiary.